This study modelled the cost-effectiveness of a transvalvular microaxial flow pump in infarct-related cardiogenic shock, for German statutory insurers. A cohort state-transition model used trial outcomes for 180 days, then chronic states with or without heart failure. The pump gave 1.06 extra QALYs at €38,121 more, or €36,083 per QALY, discounted at 3%. At an illustrative threshold of €50,000 per QALY, the probability of cost-effectiveness was 86%. Bleeding (21.8% vs 11.9%) and limb ischaemia (5.6% vs 1.1%) were more frequent with the pump. Acute payments were assumed equal between arms, and net monetary benefit remained positive below an acute payment difference of €14,703.
Why it is interesting: The pump lowered 180-day mortality but raised bleeding and limb ischaemia, and the model weighs both. The result depends on acute hospital payments not yet measured by arm.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.